Dictate anywhere on your screen, capture telehealth audio straight from the call,
and skip the second login.
Warning: Clinical review pending: not for clinical use
For clinical decision support only. Always integrate with full clinical assessment, local guidelines, and patient preferences.
The Cockcroft-Gault Creatinine Clearance (CrCl) calculator is a clinical tool for estimating renal drug elimination capacity to guide dose adjustment in patients with impaired kidney function. Calculate CrCl below:
Every summary carries citations with verbatim excerpts from the source, so you can open it, read it in context and confirm it says what the answer claims. What surfaces are decided by clinical quality, the governed alternative to pasting a clinical question into a general AI chatbot and hoping the answer holds.
Heidi Evidence draws on sources clinicians already trust, from Elsevier and DynaMed to MIMS Australia, and your organization can layer in its own regional pathways, policies, and formularies.
Heidi is the first in its field to hold ISO 42001 certification for AI management. Since Evidence is designed as a reference tool, the clinical call (and the responsibility for it) stays with you.
Evidence draws on the patient visit and its context, so the specifics travel with the question instead of being left behind. When a calculation is involved, the logic sits alongside the result, so you can see how it was reached and confirm it yourself rather than trust a black box.
Making that connection between the patient and the GP, like a puzzle fitting together.
Deborah Hawthorne
Clinicians at Connect2Care
Medical knowledge only. Not for autonomous decision making. Check sources and use your clinical judgement.
A CrCl calculator running the Cockcroft-Gault equation remains the mandated basis for DOAC dosing, and eGFR is not a valid substitute: this sits as a Grade 1A recommendation in the UK Kidney Association's October 2025 atrial fibrillation and VTE anticoagulation guidelines, with the MHRA and the NHS Specialist Pharmacy Service stating the same. The distinction is not academic, since dabigatran is contraindicated below a CrCl of 30 mL/min and reading an eGFR instead risks missing that threshold.
Beyond anticoagulation, KDIGO 2024 sets the general rule: adjust drug doses according to FDA and EMA-approved labeling, which predominantly references Cockcroft-Gault CrCl, and measure cystatin C-based eGFR when creatinine-based estimates are unreliable, as in extremes of muscle mass, older age or amputation.
Oncology runs the other way. The 2022 ADDIKD international consensus guideline, adopted by eviQ, recommends CKD-EPI eGFR rather than Cockcroft-Gault as the preferred estimate for anticancer drug dosing in kidney dysfunction.
One caveat holds across every indication: the equation assumes a stable creatinine, so in AKI it becomes unreliable and dose adjustment should rest on clinical judgment and serial creatinine values rather than a single calculated result.